These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2099739)

  • 1. Antibody-combining sites: prediction and design.
    Gregory DS; Staunton D; Martin AC; Cheetham JC; Pedersen J; Rees AR
    Biochem Soc Symp; 1990; 57():147-55. PubMed ID: 2099739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model building of antibody combining sites.
    Bajorath J; Novotny J
    Ther Immunol; 1995 Apr; 2(2):95-103. PubMed ID: 8729880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of antibody hypervariable loops reproduced by a conformational search algorithm.
    Bruccoleri RE; Haber E; Novotný J
    Nature; 1988 Oct; 335(6190):564-8. PubMed ID: 3419534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody modeling: implications for engineering and design.
    Morea V; Lesk AM; Tramontano A
    Methods; 2000 Mar; 20(3):267-79. PubMed ID: 10694450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new strategy for the generation of catalytic antibodies.
    Shokat KM; Leumann CJ; Sugasawara R; Schultz PG
    Nature; 1989 Mar; 338(6212):269-71. PubMed ID: 2922053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling of antibody-combining sites.
    Webster DM; Rees AR
    Methods Mol Biol; 1995; 51():17-49. PubMed ID: 7581695
    [No Abstract]   [Full Text] [Related]  

  • 7. The de novo design of an antibody combining site. Crystallographic analysis of the VL domain confirms the structural model.
    Essen LO; Skerra A
    J Mol Biol; 1994 Apr; 238(2):226-44. PubMed ID: 8158652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shapes of antibody binding sites: qualitative and quantitative analyses based on a geomorphic classification scheme.
    Lee M; Lloyd P; Zhang X; Schallhorn JM; Sugimoto K; Leach AG; Sapiro G; Houk KN
    J Org Chem; 2006 Jul; 71(14):5082-92. PubMed ID: 16808494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABGEN: a knowledge-based automated approach for antibody structure modeling.
    Mandal C; Kingery BD; Anchin JM; Subramaniam S; Linthicum DS
    Nat Biotechnol; 1996 Mar; 14(3):323-8. PubMed ID: 9630894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulations of a G protein-coupled receptor homology model predict dynamic features and a ligand binding site.
    Wolf S; Böckmann M; Höweler U; Schlitter J; Gerwert K
    FEBS Lett; 2008 Oct; 582(23-24):3335-42. PubMed ID: 18775703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecule evoluator. An interactive evolutionary algorithm for the design of drug-like molecules.
    Lameijer EW; Kok JN; Bäck T; Ijzerman AP
    J Chem Inf Model; 2006; 46(2):545-52. PubMed ID: 16562982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting molecular interactions and inducible complementarity: fragment docking of Fab-peptide complexes.
    Friedman AR; Roberts VA; Tainer JA
    Proteins; 1994 Sep; 20(1):15-24. PubMed ID: 7529922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking ligands onto binding site representations derived from proteins built by homology modelling.
    Schafferhans A; Klebe G
    J Mol Biol; 2001 Mar; 307(1):407-27. PubMed ID: 11243828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of metal-carbonyl-dendrimer-antibody immunoconjugates: towards a new format for carbonyl metallo immunoassay.
    Fischer-Durand N; Salmain M; Rudolf B; Vessières A; Zakrzewski J; Jaouen G
    Chembiochem; 2004 Apr; 5(4):519-25. PubMed ID: 15185376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rational construction of an antibody against cystatin: lessons from the crystal structure of an artificial Fab fragment.
    Schiweck W; Skerra A
    J Mol Biol; 1997 May; 268(5):934-51. PubMed ID: 9180382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reductionism and the search for structure-function relationships in antibody molecules.
    Van Regenmortel MH
    J Mol Recognit; 2002; 15(5):240-7. PubMed ID: 12447900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence.
    Bhasin M; Raghava GP
    Bioinformatics; 2004 Feb; 20(3):421-3. PubMed ID: 14960470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design, analysis, and potential utility of GM-CSF antagonists.
    Monfardini C; Kieber-Emmons T; VonFeldt JM; Godillot AP; Voet D; Weiner DB; Williams WV
    Proc Assoc Am Physicians; 1996 Nov; 108(6):420-31. PubMed ID: 8956365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homology-based modelling of targets for rational drug design.
    Wieman H; Tøndel K; Anderssen E; Drabløs F
    Mini Rev Med Chem; 2004 Sep; 4(7):793-804. PubMed ID: 15379646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.